ICICI Prudential Asset Management Co Ltd Increases Position in Bristol Myers Squibb Company $BMY

ICICI Prudential Asset Management Co Ltd lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 85.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 181,849 shares of the biopharmaceutical company’s stock after buying an additional 84,000 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Bristol Myers Squibb were worth $8,201,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Gateway Investment Advisers LLC increased its holdings in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC increased its holdings in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after purchasing an additional 30,909 shares during the last quarter. Commonwealth Retirement Investments LLC lifted its position in shares of Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after buying an additional 11,690 shares in the last quarter. Stephens Inc. AR boosted its stake in Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after buying an additional 32,476 shares during the last quarter. Finally, Railway Pension Investments Ltd increased its stake in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after acquiring an additional 40,300 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BMY. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Citigroup increased their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. HSBC reaffirmed a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $60.19.

Bristol Myers Squibb Stock Performance

BMY stock opened at $60.32 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The firm has a market cap of $122.85 billion, a price-to-earnings ratio of 17.49, a PEG ratio of 0.17 and a beta of 0.29. The business’s fifty day simple moving average is $56.05 and its two-hundred day simple moving average is $49.86. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the prior year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted BMY’s NDA for an iberdomide combination in relapsed/refractory multiple myeloma and granted priority review (decision due Aug. 17, 2026). This raises the chance of a new revenue stream and short/medium‑term upside if approved. FDA Accepts BMY’s NDA
• Positive Sentiment: Coverage highlighting iberdomide review and BMY’s AI alliance frames new upside scenarios beyond core franchises — supportive sentiment for medium‑term growth prospects. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Positive Sentiment: Analyst commentary continues to underscore BMY’s durable oncology franchise as a core strength, which supports baseline cash flow and reduces execution risk relative to smaller biotech peers. Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Coverage noting BMY’s relative stability vs. the broader market — useful context for defensive positioning but not an immediate catalyst. BMY Delivers Stability While S&P 500 Stays Volatile
• Neutral Sentiment: General “street” roundups summarize mixed analyst views; useful for gauging sentiment but contain no single market‑moving surprise. What Does The Street Have To Say About BMY?
• Negative Sentiment: Zacks Research issued multiple downward revisions to quarterly and FY2027 EPS (examples: Q1 2026 cut to $1.40 from $1.50; Q3 2027 to $1.51 from $1.57; FY2027 to $5.71 from $5.90). Those cuts signal the analyst community trimming growth/earnings expectations and are the primary near‑term negative driver weighing on the stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.